{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"2.290","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"772,787,887","primaryexch":"香港交易所","ric":"1875.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"K","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0479,"inline_upper_strike_price":"","sedol":"BKKLNR0","am":"186.74","iv":"","ew_strike":"","as":"2.290","geographic_focus":null,"incorpin":"香港","etp_baseCur":null,"ew_amt_os":"","bd":"2.220","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"400","update_time":"2025-09-28 00:06:03.0","lo52":"1.480","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"付山","underlying_ric":"1875.HK","hi52":"2.940","issuer_name":"東曜藥業股份有公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"2.220","mkt_cap":"1.76","f_aum_hkd":null,"ew_sub_per_to":"","ls":"2.290","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+0.030","aum":"","issued_shares_class_B":null,"vo":"82.80","secondary_listing_flag":false,"listing_date":"2019年11月8日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"東曜藥業股份有公司 - B","nm_s":"東曜藥業－Ｂ","sym":"1875","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"東曜藥業股份有限公司是一家臨牀階段生物製藥公司，主要從事開發及商業化腫瘤藥物及療法。該公司的主營業務在中華人民共和國從事抗腫瘤藥物的研究與開發、生產及營銷、合約開發生產組織（CDMO）/合約生產組織（CMOJ）業務以及自主開發生物藥物的對外許可。該公司擁有針對各類癌症的在研腫瘤藥物管線，當中包括單克隆抗（mAb）及抗體偶聯藥物（ADC）。該公司已建立起一個集發現、產程開發、質量管理臨牀前及臨牀開發以及商業規模的生產基地和銷售及營銷能力於一體的綜合內部平臺。該公司主要在中國國內市場開展業務。","op":"2.280","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園1期<br/>19樓1918室","pc":"+1.33","days_to_expiry":null,"underlying_code":null,"pe":"45.26","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"2.260","isin":"HK0000545266","moneyness":""}},"qid":"1759074952570"}
